Synergistic Effects of BPC-157, KPV, Thymosin Alpha-1, GHK-Cu, and Targeted Nutritional Cofactors on Bell’s Palsy Reversal in a Facial Nerve Crush Murine Model.docx
physician_protocol · expert_opinion · status: needs_provider_review
Metadata
Author: —
Citation: —
Embedding: pending
File: —
Summary (generated — provider review required)
Synergistic Effects of BPC-157, KPV, Thymosin Alpha-1, GHK-Cu, and Targeted Nutritional Cofactors on Bell’s Palsy Reversal in a Facial Nerve Crush Murine Model Abstract - Read the highlighted areas for the solutions !!!! This study evaluates the combined administration of BPC-157 (500 mcg subcutaneously twice daily), KPV (500 mcg subcutaneously twice daily), Thymosin Alpha-1 (1.5 mg subcutaneously three times weekly), GHK-Cu (2 mg subcutaneously daily), Benfotiamine (B1, 500 mg daily orally), Methylcobalamin (B12, 500 mcg three times daily orally), Zinc (30 mg daily orally), Vitamin D3 (5,000 IU daily orally), Vitamin K2 (200 mcg daily orally), and Folate (500 mcg daily orally) on Bell’s palsy reversal in a facial nerve crush injury model in adult male C57BL/6 mice over a 12-week period. Primary outcomes included facial nerve functional recovery (whisker movement score and eye blink reflex) and histological nerve regeneration (axon count and myelin thickness via toluidine blue staining).
The original source document remains the source of truth. Generated summaries are not authoritative.
Linked assets (7) · phenotypes (2)
evidence_reference, dosing_reference, safety_reference, mechanism, monitoring_reference
Phenotypes: neuroinflammation, mitochondrial_dysfunction
Evidence claims (22) · review items (15)
dosing · pending
Vitamin D3: 5,000 IU daily orally (8 AM).
dosing · pending
This study evaluates the combined administration of BPC-157 (500 mcg subcutaneously twice daily), KPV (500 mcg subcutaneously twice daily), Thymosin Alpha-1 (1.5 mg subcutaneously three times weekly), GHK-Cu (2 mg subcutaneously daily), Benfotiamine (B1, 500 mg daily orally), Methylcobalamin (B12, 500 mcg three times daily orally), Zinc (30 mg daily orally), Vitamin D3 (5,000 IU daily orally), Vitamin K2 (200 mcg daily orally), and Folate (500 mcg daily orally) on Bell’s palsy reversal in a facial nerve crush injury model in adult male C57BL/6 mice over a 12-week period.
outcome · pending
Primary outcomes included facial nerve functional recovery (whisker movement score and eye blink reflex) and histological nerve regeneration (axon count and myelin thickness via toluidine blue staining).
outcome · pending
The combination improved whisker movement score by 65%, restored eye blink reflex in 85% of treated mice, increased axon count by 55%, reduced inflammation by 50%, eliminated detectable oxidative stress (ROS/MDA undetectable in 85% treated), enhanced ATP production by 45%, and improved grip strength by 35% compared to crush-injury controls.
safety · pending
No adverse effects were observed.
mechanism · pending
’s palsy reversal through tissue repair, anti-inflammatory, neuroprotective, and mitochondrial mechanisms.
outcome · pending
BPC-157 promotes neural repair and reduces inflammation in peripheral nerve injury models.
regulatory · pending
GET EVERYTHING HERE ⬇️ https://elitebiogenix.com/ Work with Dr Trevor Bachmeyer apply@unlockthecard.com Materials and Methods Ethical Statement Approved by the Institutional Animal Care and Use Committee (IACUC) under protocol #2026-MUR-061, complying with the Guide for the Care and Use of Laboratory Animals (National Research Council, 2011) and EU Directive 2010/63/EU.
dosing · pending
Compound Administration Compounds (>98% purity, certified suppliers) administered using exact specified dosages without alteration: BPC-157: 500 mcg subcutaneously twice daily (8 AM/PM).
dosing · pending
KPV: 500 mcg subcutaneously twice daily (8 AM/PM).
dosing · pending
Thymosin Alpha-1: 1.5 mg subcutaneously three times weekly (Mon/Wed/Fri, 8 AM).
dosing · pending
GHK-Cu: 2 mg subcutaneously daily (8 AM).
dosing · pending
Benfotiamine (B1): 500 mg daily orally (8 AM).
dosing · pending
Methylcobalamin (B12): 500 mcg three times daily orally (8 AM/PM).
dosing · pending
Zinc: 30 mg daily orally (8 AM).
dosing · pending
Vitamin K2: 200 mcg daily orally (8 AM).
dosing · pending
Folate: 500 mcg daily orally (8 AM).
outcome · pending
GET EVERYTHING HERE ⬇️ https://elitebiogenix.com/ Work with Dr Trevor Bachmeyer apply@unlockthecard.com Outcome Measures
safety · pending
Results Survival 100%; no toxicity.
mechanism · pending
The protocol achieved complete Bell’s palsy reversal: BPC-157/KPV/GHK-Cu promoted neural repair and anti-inflammation, Thymosin Alpha-1 modulated immunity, supplements supported nerve myelination and antioxidant defense.
monitoring · pending
Monitoring Daily: Symptom diary (facial movement 0-10).
safety · pending
Safety Mild reactions possible (injection sites).
Extracted chunks (7)
858 approx tokens across 7 chunks.